JAMA Oncology Author Interviews

Interviews with authors of articles from JAMA Oncology. JAMA Oncology is the definitive journal for scientists, clinicians, and trainees in the field of oncology worldwide. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers. JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.

Consistent Adherence to Physical Activity Guidelines and Digestive System Cancer Risk and Mortality

Interview with Yiwen Zhang, PhD, and Edward L. Giovannucci, MD, ScD, authors of Consistent Adherence to Physical Activity Guidelines and Digestive System Cancer Risk and Mortality. Hosted by Vivek Subbiah, MD. Related Content: Consistent Adherence to Physical Activity Guidelines and Digestive System Cancer Risk and Mortality Long-Term Physical Activity for Prevention of Digestive System Cancers—Consistency Is Key

10-30
12:29

Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer

Interview with Jiyoung Ahn, PhD, author of Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer. Hosted by Vivek Subbiah, MD. Related Content: Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer

09-18
13:26

Proportional Sedation for Persistent Agitated Delirium in Palliative Care

Interview with David Hui, MD, and Eduardo Bruera, MD, authors of Proportional Sedation for Persistent Agitated Delirium in Palliative Care: A Randomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Content: Proportional Sedation for Persistent Agitated Delirium in Palliative Care

07-31
17:43

New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance

Interview with Thorir Einarsson Long, MD, PhD, and Ola Landgren, MD, PhD, authors of New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance. Hosted by Vivek Subbiah, MD. Related Content: New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance

05-29
18:54

Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury

Interview with Shruti Gupta, MD, MPH, author of Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury. Hosted by Vivek Subbiah, MD. Related Content: Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury

04-24
12:23

Accelerated Aging in Survivors of Childhood Cancer

Interview with Jennifer M. Yeh, PhD, and Lisa R. Diller, MD, authors of Accelerated Aging in Survivors of Childhood Cancer—Early Onset and Excess Risk of Chronic Conditions. Hosted by Vivek Subbiah, MD. Related Content: Accelerated Aging in Survivors of Childhood Cancer—Early Onset and Excess Risk of Chronic Conditions On Accelerated Aging—A Phenomenon in Survivors of Childhood Cancer

03-20
19:19

Academic-Community Partnership and Deaths in Promyelocytic Leukemia

Interview with Anand P. Jillella, MD, author of Academic-Community Partnership and Deaths in Promyelocytic Leukemia: The Nonrandomized ECOG-ACRIN EA9131 Trial. Hosted by Vivek Subbiah, MD. Related Content: Academic Community Partnership in Acute Promyelocytic Leukemia and Early Mortality

02-27
18:46

Intracranial Outcomes in Melanoma Brain Metastases After Anti–PD-1 Therapy

Interview with Michael A. Postow, MD, author of Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti–PD-1 Therapy. Hosted by Vivek Subbiah, MD. Related Content: Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti–PD-1 Therapy

01-30
11:55

Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020

Interview with Katrina A. B. Goddard, PhD, author of Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020. Hosted by Vivek Subbiah, MD. Related Content: Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020

12-05
16:08

Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib

Interview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Content: Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib

11-21
18:46

Anti–PD-L1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma

Interview with Maria E. Cabanillas, MD, author of Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Content: Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma

10-24
20:41

Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer

Interview with Eileen M. O'Reilly, MD, author of Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer. Hosted by Vivek Subbiah, MD. Related Content: Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer

09-05
17:15

Identification of Immune Checkpoint Inhibitor–Induced Diabetes

Interview with Michelle Rengarajan, MD, PhD, author of Identification of Immune Checkpoint Inhibitor–Induced Diabetes. Hosted by Vivek Subbiah, MD. Related Content: Identification of Immune Checkpoint Inhibitor–Induced Diabetes

08-29
14:36

Neoadjuvant Exercise Therapy in Prostate Cancer

Interview with Lee W. Jones, PhD, author of Neoadjuvant Exercise Therapy in Prostate Cancer: A Phase 1, Decentralized Nonrandomized Controlled Trial. Hosted by Vivek Subbiah, MD. Related Content: Neoadjuvant Exercise Therapy in Prostate Cancer

07-18
19:01

Endometrial Thickness as Diagnostic Triage for Endometrial Cancer in Black Individuals

Interview with Kemi M. Doll, MD, MSCR, author of Endometrial Thickness as Diagnostic Triage for Endometrial Cancer Among Black Individuals. Hosted by Vivek Subbiah, MD. Related Content: Endometrial Thickness as Diagnostic Triage for Endometrial Cancer Among Black Individuals

06-27
15:04

T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy

Interview with Roni Shouval, MD, PhD, author of T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy. Hosted by Vivek Subbiah, MD. Related Content: T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy

04-18
19:57

Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time

Interview with Tobias Janowitz, MD, PhD, and Karen Winkfield, MD, PhD, authors of Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time. Hosted by Vivek Subbiah, MD. Related Content: Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time

03-21
25:53

Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer

Interview with José P. Leone, MD, author of Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer. Hosted by Nora L. (Mary) Disis, MD. Related Content: Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer

02-29
14:26

Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US

Interview with Sajid A. Khan, MD, author of Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US. Hosted by Mary L. (Nora) Disis, MD. Related Content: Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US

01-04
17:31

Atezolizumab in Combination With Carboplatin in Metastatic TNBC

Interview with Jennifer A. Pietenpol, PhD, Brian D. Lehmann, PhD, and Vandana G. Abramson, MD, authors of Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial. Hosted by Mary L. (Nora) Disis, MD. Related Content: Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer

12-14
18:18

Recommend Channels